AstraZeneca's vaccine study put on hold
Nicolas Suiffet September 9, 2020 8:48 AM
AstraZeneca's, a pharmaceutical group, Covid-19 vaccine phase 3 trial has been put on hold due to a suspected serious adverse reaction in a participant in the U.K
AstraZeneca's Covid-19 vaccine phase 3 trial has been put on hold due to a suspected serious adverse reaction in a participant in the U.K., according to the Stat News.
From a chartist point of view, the stock price remains in consolidation mode below the key resistance threshold at 8736p. A morning star pattern has formed but the signal still needs to be confirmed. The daily Relative Strength Index (RSI, 14) is reversing up but remains below 50% and remains capped by a declining trend line. The 20/50DMAs still play a resistance role. As long as 8736p is resistance, the risk of a break below the swing low at 7930p will remain high. Alternatively, a push above 8736p would reinstate a bullish bias with 9350p as first target.
Source: GAIN Capital, TradingView
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.